🧾 What This Document Is

This is Quest Diagnostics' definitive proxy statement (DEF 14A). Think of it as the company's official "corporate report card" and instruction manual for its annual shareholder meeting. It's not an earnings report, but a document that explains what shareholders will vote on, who runs the company, and how the top bosses are paid.

👉 In simple terms: If you own a piece of Quest Diagnostics, this tells you what's on the agenda for the big annual meeting and gives you the info you need to vote your shares.

🏢 What The Company Does

Quest Diagnostics is a giant in the medical laboratory testing industry. They don't usually deal with you directly—instead, they process tests ordered by your doctor, hospital, or health insurer.

Their simple mission: "Working together to create a healthier world, one life at a time." They do this by providing testing insights that help in diagnosis, prevention, and treatment.

Key business pillars:

Collaborating: Partnering with hospitals and health plans.
Advanced Tests: Offering high-tech tests in areas like oncology (cancer) and brain health (e.g., an Alzheimer's blood test).
Consumer Growth: Expanding their QuestHealth.com service where people can order their own tests.
Efficiency Tech: Using automation and AI in labs to work faster and smarter.

📅 The Big Vote: Annual Meeting Details

Shareholders are being asked to vote on four main items at the meeting on May 20, 2026.

What You're Voting On	Board's Recommendation
1. Elect 11 Directors to the board	FOR each nominee
2. Approve executive pay (advisory vote)	FOR
3. Ratify the auditor (PricewaterhouseCoopers)	FOR
4. Consider a stockholder proposal for an independent board chair	AGAINST

👉 Why it matters: The "Say on Pay" vote (Item 2) is a chance for shareholders to give a thumbs-up or thumbs-down on the top executives' compensation package. The stockholder proposal (Item 4) suggests splitting the Chairman and CEO roles (both held by James Davis). The board opposes this, believing their current structure is effective.

👥 The Board of Directors: Who's In Charge?

The board oversees the company for shareholders. The 11 nominees are a mix of experts from healthcare, finance, tech, and operations.

Notable Skills on the Board:

Healthcare & Science: Several members, including a top cancer doctor from Memorial Sloan Kettering.
CEO Experience: Many have run large companies (e.g., Walgreens, Campbell Soup, FedEx).
Tech & AI: Expertise from leaders in information technology.
Independence: 10 of the 11 nominees are independent (not company employees). Only CEO James Davis is not.

Newest Nominee: Timothy Wentworth (former Walgreens CEO) joined in March 2026, adding significant health plan and pharmacy experience.

💰 How Bosses Get Paid: The Executive Pay Plan

Quest's philosophy is "pay for performance." A large chunk of executive pay is not guaranteed—it's tied to hitting company goals.

2025 Pay Mix for Named Executives:

Long-Term Incentives (83% of target pay):
- 50% in Performance Shares: Payout depends on 3-year goals (revenue growth, return on capital, stock performance vs. peers).
- 25% in Stock Options
- 25% in Restricted Stock Units (RSUs)
Short-Term Incentives (16%): Annual cash bonus based on yearly financial and operational targets.
Base Salary (1%): Fixed cash pay.

Did they earn it?

For the 3-year period ending 2025, executives earned 154% of their target performance share payout. This means the company hit many of its long-term goals.
The average 2025 annual cash bonus paid out at 116% of target.

📈 2025 Business Performance Highlights

The proxy details a strong 2025, used to justify executive pay.

Financials:

Revenue: $11.04 Billion (Up 11.8% from 2024)
Profit (Adjusted EPS): $9.85 per share
Cash from Operations: $1.89 Billion

Strategic Wins:

Advanced Diagnostics: Tests in oncology, brain health, etc., surpassed $1 Billion in revenue.
Consumer Lab: QuestHealth.com now offers over 150 tests with 45 million+ users in its portal.
Hospital Partnerships: Their "Co-Lab Solutions" for hospitals generated about $800 million.
Tech & Efficiency: Major partnerships with Google (for AI/data) and Epic (for healthcare software integration).

💸 Giving Cash Back to Owners

The company has been a steady returner of capital to its shareholders.

Dividend Increase: In Feb 2026, raised the quarterly dividend by ~7.5% to $0.86 per share. This is the 15th increase since 2012.
Stock Buybacks: Repurchased over $450 million of its own stock in 2025.
Long-Term Track Record: Since 2012, has returned approximately $11.7 billion to shareholders through buybacks and dividends.

⚖️ Strengths & Risks (The Big Picture)

👍 Strengths:

Market Leader: Scale, access to over 90% of insured lives, and a trusted brand.
Innovation Engine: Investing in advanced diagnostics and consumer-facing tech.
Strong Cash Flow: Generates ample cash to invest in growth and reward shareholders.
Aligned Pay: Executive pay is heavily tied to performance metrics that should benefit long-term shareholders.

⚠️ Risks & Considerations:

Healthcare Policy Changes: Business depends on insurance reimbursement rates and government health programs.
Competition: Faces competition from other large labs and hospital in-house labs.
Execution Risk: Success depends on integrating acquisitions and new technology (like AI) smoothly.
Board Structure: The stockholder proposal highlights a governance debate over combining the Chairman and CEO roles.

🔮 What's Next?

The company is focused on its "Quest Way" strategy:

Grow through collaboration with health systems and plans.
Lead in innovation, especially in advanced diagnostics.
Empower consumers via QuestHealth.com.
Drive efficiency through projects like "Project Nova" (a billing system overhaul) and expanded AI use.

🧠 The Analogy

Think of this proxy statement like the playbook and report card for a professional sports team's ownership meeting. The board of directors is the governing committee up for re-election. The executive compensation plan is the coaches' and star players' contracts—showing how much they get paid only if the team wins (hits financial goals). The business highlights are last season's stats and highlights reel. And the shareholder proposal is a fan vote suggesting a change in team management structure.

🧩 Final Takeaway

This proxy shows a company with strong recent financial performance and a clear strategy, asking shareholders to endorse its leadership and pay practices. The core decision for investors is whether to support the current board and its philosophy—including the combined CEO/Chairman role—or send a message via the stockholder proposal. The substantial "pay-for-performance" outcomes for executives reflect a company that has been hitting its targets.

QUEST DIAGNOSTICS INC — DEF 14A Filing